Feasibility Study for Training Pump Naïve Subjects To Use The Paradigm® System And Evaluate Effectiveness (STAR2)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00530023|
Recruitment Status : Completed
First Posted : September 17, 2007
Results First Posted : June 10, 2011
Last Update Posted : June 10, 2011
|Condition or disease||Intervention/treatment||Phase|
|Type 1 Diabetes||Device: MiniMed Paradigm REAL-Time System||Phase 4|
Many subjects with Type 1 diabetes continue to manage their disease utilizing multiple daily injections, but despite frequent blood glucose checks, are unable to control their glycemic variability or lower their A1C levels. The MiniMed Paradigm REAL-Time System transmits sensor glucose values to the insulin pump every 5 minutes, allowing users to view their current glucose values as well as glycemic excursions and trends over a 24-hour period. The System will also alert users of high and low glucose levels, allowing subjects and their clinicians to make carefully monitored modifications to therapy. Additionally, data can be uploaded from the monitor into a personal computer, allowing the subject and clinician to see a complete picture of trends over time.
Subjects learning this technology would require a new approach to training if they were to master operation of an insulin pump, make effective use of the sensor technology and understand the complete picture provided by the software component. Subjects will be trained to first use the insulin pump, add the sensor and then utilize the software and the effectiveness of the training methods and timing will be measured using questionnaires designed to evaluate understanding of the device, Self Efficacy and User Acceptance. The group wearing the System will also be compared to subjects that continue on their current MDI therapy over a 15-week time period.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||29 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Pilot Study To Identify Effective Methods Of Training Pump Naïve Subjects To Use The Paradigm® 722 System And To Describe Clinical Effectiveness Compared To Subjects Continuing With Multiple Dose Injections (MDI) of Insulin|
|Study Start Date :||February 2006|
|Actual Primary Completion Date :||September 2006|
|Actual Study Completion Date :||September 2006|
Active Comparator: 1. 722
722 arm: MiniMed Paradigm REAL-Time System
Device: MiniMed Paradigm REAL-Time System
MiniMed Paradigm 722 insulin pump The transmitter The sensor Paradigm Link Glucose Meter The ComLink
No Intervention: 2. Multiple Daily Injections (MDI)
MDI arm: Continue with currently prescribed Multiple Daily Injection therapy. No change in treatment or regime for study.
- Change in A1C From Baseline to Week 15 [ Time Frame: Baseline and 15 weeks ]Change in A1C measured from Baseline to week 15 will be compared. A1C measured as percent of glycated hemoglobin using a standardized assay for all subjects.
- Incidence of Severe Hypoglycemia Events Baseline to Week 15 [ Time Frame: Baseline and 15 weeks ]The total number of severe hypoglycemia events, defined as episodes requiring assistance from another person (i.e., subject is unable to treat self and requires carbohydrate or glucagon or other resuscitative actions) compared between the two study arms from Baseline to Week 15.
- Blood Glucose Monitoring System - Ratings Questionnaire (BGMS-RQ) Assessed at Baseline and Week 15 [ Time Frame: Baseline and 15 weeks ]Questionnaire measuring overall satisfaction with the relevant blood glucose monitoring system. Assessed at Baseline and Week 15 and compared between arms. Likert scale used with responses graded as the lowest number being the least acceptable and the highest number the most acceptable. The scoring was then transformed to a 0 - 100 scale again with the higher number representing the most acceptable response.
- Insulin Delivery System - Ratings Questionnaire (IDS-RQ) Assessed at Baseline and Week 15 [ Time Frame: Baseline and 15 weeks ]Questionnaire measuring overall satisfaction with the relevant insulin delivery system. Assessed at Baseline and Week 15 and compared between arms. Likert scale used with responses graded as the lowest number being the least acceptable and the highest number the most acceptable. The scoring was then transformed to a 0 - 100 scale again with the higher number representing the most acceptable response.
- Hypoglycemia Fear Scale (HFS) Assessed at Baseline and Week 15 [ Time Frame: Baseline and 15 weeks ]Questionnaire evaluating change in the subjects' fear of potential hypoglycemia events assessed Week 15 and compared between arms. Likert scale of 0 - 4 used with responses graded as the lowest number being the most acceptable and highest number the least acceptable. The questionnaire has two sections, Behavior and Worry with a maximum possible score of 60 for Behavior (15 X 4) and 72 for Worry (18 X 4). The total combined scoring of these two sections was then assessed at Baseline and Week 15 and the change from Baseline to Week 15 for each arm reported as the end of study result.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00530023
|United States, California|
|Diabetes Treatment Center, Loma Linda University|
|Loma Linda, California, United States, 92354|
|United States, Oregon|
|Portland Diabetes & Endocrinology|
|Portland, Oregon, United States, 97210|
|Study Director:||Scott W Lee, MD||Medtronic Diabetes|